Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell…
NCT00003280 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003280 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma |
| Official title | A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4 |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | rituximab |
| Enrollment | 240 |
| Start date | Jan 1, 1998 |
| Primary completion | Mar 1, 2002 |
| Completion | Mar 1, 2002 |
| First posted | Sep 24, 2003 |
| Last update posted | May 15, 2019 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: